08:00 , Jan 7, 2002 |  BioCentury  |  Finance

Ebb & Flow

InterMune (ITMN) lost $207 million of its value last week as investors dumped shares on rumors that the company was seeing a larger-than-expected dropout rate for its Phase III trial of Actimmune interferon gamma-1b in...
08:00 , Dec 20, 2001 |  BC Extra  |  Financial News

Xcyte raises $13.2 million

Xcyte Therapies raised $13.2 million in a venture financing. Investors included China Development Industrial Bank; CDIB Biotech; MPM Capital; Alta Partners; Arch Venture Partners; Sprout Group; Vulcan Ventures; and Tredegar . The financing comes less...
07:00 , Sep 24, 2001 |  BioCentury  |  Finance

Ebb & Flow

Amid the sucking sound of the WTC market meltdown, Actelion (SWX:ATLN) was one of the few companies rewarded for key milestones last week (see Cover Story). The stock closed the week up CHF3 to CHF41...
07:00 , Sep 19, 2001 |  BC Extra  |  Financial News

PTC raises $40 million

PTC raised $40 million in a private round led by CSFB Private Equity; Vulcan Ventures; and Bay City Capital. Other investors included CDIB Biotech; China Development Industrial Bank; Delphi Ventures; HealthCap; The Manufacturers Life Insurance...